VIR in the 13F filings
Vir Biotechnology Inc · CUSIP 92764N102
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 15 May 2024
- latest of these filings; the earliest 1 May 2024
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 2 listed it in both
- Shares listed
- 4,313,108
- combined, among listed positions
- Reported value
- $44m
- combined, at the quarter end
Among the 93 comparable managers: 1 buyer (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +57,559.
Managers listing VIR in Q1 2024
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Baillie Gifford & Co | 3,947,065 | $40m | under 0.1% | Trimmed | -18,484 | 1 May 2024 (the filing on sec.gov) |
| Hudson Bay Capital Management LP | 285,000 | $2.9m | under 0.1% | Trimmed | -5,000 | 15 May 2024 (the filing on sec.gov) |
| Winton Group Ltd | 81,043 | $821k | 0.06% | New | new | 14 May 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Winton Group Ltdnew position · 81,043 shares now+81,043
Reductions
- Baillie Gifford & Coexisting position · 3,947,065 shares now-18,484
- Hudson Bay Capital Management LPexisting position · 285,000 shares now-5,000
New positions and exits
New (1)
- Winton Group Ltd$821k
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2019 | 1 | $6.3m | n.a. | n.a. |
| Q1 2020 | 1 | $4.5m | n.a. | n.a. |
| Q2 2020 | 3 | $223m | n.a. | n.a. |
| Q3 2020 | 2 | $199m | n.a. | n.a. |
| Q4 2020 | 3 | $189m | n.a. | n.a. |
| Q1 2021 | 3 | $302m | n.a. | n.a. |
| Q2 2021 | 3 | $292m | n.a. | n.a. |
| Q3 2021 | 3 | $272m | n.a. | n.a. |
| Q4 2021 | 4 | $375m | n.a. | n.a. |
| Q1 2022 | 3 | $303m | n.a. | n.a. |
| Q2 2022 | 4 | $176m | n.a. | n.a. |
| Q3 2022 | 4 | $111m | n.a. | n.a. |
| Q4 2022 | 2 | $102m | n.a. | n.a. |
| Q1 2023 | 4 | $198m | n.a. | n.a. |
| Q2 2023 | 5 | $189m | n.a. | n.a. |
| Q3 2023 | 2 | $39m | n.a. | n.a. |
| Q4 2023 | 2 | $43m | 1 | 1 |
| Q1 2024 | 3 | $44m | 1 | 2 |
| Q2 2024 | 5 | $42m | 4 | 1 |
| Q3 2024 | 5 | $25m | 4 | 1 |
| Q4 2024 | 4 | $14m | 2 | 2 |
| Q1 2025 | 1 | $5.1m | 0 | 1 |
| Q2 2025 | 1 | $4.0m | 0 | 0 |
| Q4 2025 | 2 | $9.1m | 15 | 10 |
| Q1 2026 | 3 | $17m | 18 | 10 |
| Q2 2026 | 3 | $73m | 12 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VIR and GILD →VIR and AMGN →VIR and ARGX →Choose a stock to compare with VIR →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VIR, latest filings →Back to the 13F Explorer →